Fig. 4
Antitumor and survival-extending properties of a hypomethylating agent (DAC) combined with MC180295. A Antitumor effects of MC180295 and MC180295 + DAC. NSG mice were inoculated (s.c.) with 2 × 106 SW48 cells. Eleven days later, when tumors were palpable, 20 mg/kg MC180295 or vehicle were administered (i.p.) q.o.d. 0.5 mg/kg DAC was administered (i.p.) daily. Tumor sizes were measured using a caliper. B Mouse survival in days. 20 mg/kg MC180295 was administered (i.p.) q.o.d. 0.5 mg/kg DAC was administered (i.p.) daily. C NSG mice were inoculated (i.p.) with 5 × 105 MV4-11-luc cells. Four days later, when substantial tumor burden was evident by bioluminescence imaging, MC180295 (20 mg/kg) or vehicle were administered (i.p.) every other day. 0.5 mg/kg DAC was administered (i.p.) daily. Luciferase expression was quantified and calculated. D IP-administered MC180295 and DAC + MC180295 significantly extended survival in MV4-11 model mice. E Antitumor effects of MC180380 and MC180380 + DAC. NSG mice were inoculated (s.c.) with 2 × 106 SW48 cells. Eleven days later, when tumors were palpable, 10 mg/kg MC180380, 20 mg/kg MC180380, or vehicle was administered (i.p.) q.o.d. 0.5 mg/kg DAC was administered (i.p.) daily. Mouse survival shown in days. Significances were calculated using log-rank (Mantel-Cox) or Student's t tests. Data are shown as means ± SEMs. ***p < 0.001